AVACINCAPTAD PEGOL SODIUM generics — when can they launch?
AVACINCAPTAD PEGOL SODIUM (AVACINCAPTAD PEGOL SODIUM) · · 6 active US patents · 0 expired
Where AVACINCAPTAD PEGOL SODIUM sits in the generic timeline
All listed Orange Book patents for AVACINCAPTAD PEGOL SODIUM have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 5 patents
- Composition of Matter — 1 patent
FDA U-codes carved out by AVACINCAPTAD PEGOL SODIUM patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-3673 | (no description) |
Sample patent estate
Showing 6 of 6 active US patents. View full estate on the AVACINCAPTAD PEGOL SODIUM drug page →
-
This patent protects a method of using nucleic acid therapeutics to treat complement-related disorders.USPTO title: Aptamer therapeutics useful in the treatment of complement-related disorders
-
This patent protects a method of using nucleic acid therapeutics to treat complement-related disorders.USPTO title: Aptamer therapeutics useful in the treatment of complement-related disorders
-
This patent protects a nucleic acid therapeutic for treating complement-related disorders.USPTO title: Aptamer therapeutics useful in the treatment of complement-related disorders
-
This patent protects methods for treating or preventing ophthalmological conditions by administering certain drugs, including Antagonist A or an anti-C5 agent, to a subject in need of treatment.USPTO title: Methods for treating or preventing ophthalmological conditions
-
This patent protects methods for treating or preventing ophthalmological conditions by administering Antagonist A or an anti-C5 agent, such as ARC1905, to a subject in need thereof.USPTO title: Methods for treating or preventing ophthalmological conditions
-
This patent protects methods for treating or preventing ophthalmological conditions by administering Antagonist A or an anti-C5 agent, such as ARC1905, to a subject in need thereof.USPTO title: Methods for treating or preventing ophthalmological conditions
Sources
- FDA Orange Book — patents listed against AVACINCAPTAD PEGOL SODIUM (NDA filed 2023)
- AVACINCAPTAD PEGOL SODIUM drug profile — full patent estate, indications, clinical trials, pricing
- Patent cliff 2026 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on AVACINCAPTAD PEGOL SODIUM — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →